Novartis AG (NVS) Stock

Olema Pharmaceuticals, Inc. has made a deal with Novartis to secure KISQALI for their upcoming phase 3 OPERA-02 study, which will focus on patients with ER+/HER2- metastatic breast cancer and is set to begin in mid-2025. Results from the current phase 3 OPERA-01 study, which is testing palazestrant as a standalone treatment for the same patient group, are anticipated in 2026. The worldwide market for breast cancer is expected to exceed $89.01 billion by 2034.

An income investor purchases shares in a company that pays dividends with the hope that the company will not stop these payments. In fact, dividend investors prefer that these payouts continue and increase for as long as they can, ideally indefinitely.

Novartis has received approval from the European Commission for Kisqali, which is now available for a wide range of patients with HR+/HER2- early breast cancer who are at a high risk of returning.

On November 27, 2024, in Basel, Novartis revealed that the European Commission has given the green light for Kisqali® (ribociclib) to be used alongside an aromatase inhibitor for treating patients with early breast cancer that is hormone receptor-positive and HER2-negative, who are at a high risk of recurrence.

On November 25, 2024, in Basel, Novartis will share findings from over 65 abstracts, which include trials started by researchers, at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH) and the 2024 San Antonio Breast Cancer Symposium® (SABCS).

NVS anticipates that sales will grow at a rate of 6% per year from 2023 to 2028, an increase from the previous estimate of 5%. The company has also purchased Kate Therapeutics to enhance its collection of gene therapies.

On Thursday, the CEO of Novartis mentioned that the launch of the blood-cancer drug pelabresib, which came from their acquisition of Morphosys, might be postponed until 2027 or even later. However, getting approval for the drug will rely on additional safety information.

On Thursday, Novartis increased its sales forecast for the medium term, expecting a 6% annual growth until 2028. This growth is supported by the strong performance of its recently launched drugs and the potential for new products to enter the market soon.

An announcement has been made regarding an upgrade to the mid-term sales forecast, now expecting a +6% CAGR from 2023 to 2028 and +5% from 2024 to 2029. The company is experiencing strong growth with eight brands that have the potential for peak sales between USD 3 billion and USD 8 billion, along with over 30 promising medicines in development. This update was shared ahead of the Meet Novartis Management event for investors and analysts in London on November 21, 2024.